HR Execs on the Move

SutroVax

www.sutrovax.com

 
SutroVax is a biopharmaceutical company dedicated to the delivery of best-in-class conjugate vaccines and novel complex antigen-based vaccines to prevent serious infectious diseases. SutroVax`s lead product candidate is a pneumococcal conjugate vaccine (PCV) that is designed to prevent invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae. SutroVax`s broad-spectrum PCV is designed to provide expanded protection against circulating strains of pneumococcus and has the potential to replace the current vaccines used in infants and adults. The current mainstay vaccine only covers approximately 40% of the circulating strains causing IPD yet generates $6B in annual sales. SutroVax has generated positive pre-clinical proof-of-concept ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.sutrovax.com
  • 353 Hatch Drive
    Foster City, CA USA 94404
  • Phone: 650.837.0111

Executives

Name Title Contact Details
Karen Alderete
 Director, Human Resources and Administration Profile

Similar Companies

Capital Technology Information Services

Capital Technology Information Services is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cellular Genomics

Cellular Genomics, Inc. is a Branford, CT-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Meso Scale Discovery

Meso Scale Discovery is a Gaithersburg, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mirus Bio

Mirus Bio is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Fate Therapeutics

Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company`s immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). The Company`s immuno-regulatory product candidates include ProTmune™, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA.